Zogenix — Investor Presentation (January 2017)
22 slides from Zogenix's investor presentation, Jan 9, 2017
Slide 1: Company Presentation January 2017
Company Presentation January 2017 NASDAQ: ZGNX Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming
Slide 3: Highly Focused on Developing and Commercializing Therapies for Orphan CNS Disorders
ZX008 (Low Dose Fenfluramine) for the Treatment of Uncontrolled Seizures DRAVET SYNDROME Phase 3 Studies Underway with First Top Line Results Q2 2017 Highly Focused on Developing and Commercializing Therapies for Orphan CNS Disorders LENNOX GASTAUT SYNDROME Targeting Phase 3 Study Initiation Mid-201
Slide 4: ZX008 Overview
Exclusive World-Wide Rights Orphan Drug Designation in U.S. and E.U. in Dravet Syndrome Fast Track Designation for Development in Dravet Syndrome On-Going Phase 3 Program in Dravet Syndrome; Multiple Data Readouts in 2017 Seeking IND Acceptance to Commence Phase 3 Clinical Development in Lennox Gast
Slide 5: Dravet Syndrome: Intractable, Severe Epilepsy Which Begins in Infancy
Dravet Syndrome Genetic epilepsy syndrome (SCN1A) => developmental encephalopathy Pharmaco-resistant epilepsy Intellectual disability Other comorbidities – ADHD, behavior, crouch gait Recent incidence study 1/15,700 births May be higher due to undiagnosed or mis-diagnosed cases Higher incidence of s
Slide 6: Low Dose Fenfluramine: Long Term Efficacy and Safety in Treating Dravet Syndrome
Low Dose Fenfluramine: Long Term Efficacy and Safety in Treating Dravet Syndrome – Original Cohort First Report – Epilepsia (2012) Long-term open-label study of fenfluramine adjunctive anticonvulsant therapy 12 Dravet syndrome patients, age 9 months to 13 years (11 with confirmatory genetic mutation
Slide 7: Prospective Study of a New Cohort Confirms Earlier Findings of Efficacy
Results Rapid and sustained reduction in major motor seizures following initiation of fenfluramine 76% median reduction in monthly seizures over the entire study period, which ranged from 0.8 to 5.6 years (average = 2.7 years) The most common AE’s - somnolence (n=5) and anorexia (n=4) No discontinua
Slide 8: Research on Potential Anti-Seizure Mechanisms of Fenfluramine
Research on Potential Anti-Seizure Mechanisms of Fenfluramine Serotonin Zebrafish (-/-) scn1Lab mutant model of Dravet syndrome demonstrates anti-seizure activity of fenfluramine via 5HT1D, 2A and 2C receptor stimulation 1 Sigma-1 Fenfluramine binds to sigma-1 receptors and alters activity of the si
Slide 9: ZX008 Clinical Program in Dravet Syndrome
ZX008 Clinical Program in Dravet Syndrome Clinical Program includes three double-blind, randomized, controlled 12-week efficacy and safety trials (RCTs) of ZX008 as adjunctive treatment for seizures in children with Dravet syndrome Studies 1501, 1502: identical trials running in North America (1501)
Slide 10: Design of Phase 3 Safety and Efficacy Studies 1501 and 1502
Design of Phase 3 Safety and Efficacy Studies 1501 and 1502 Two Identical Placebo Controlled Studies US/Canada: ZX008-1501 Europe/ROW: ZX008-1502 Maximum Daily Dose of 30mg Long Term Open Label Extension 6 WEEKS BASELINE OBSERVATION Screening Open Label Safety Study N = 105 Ages 2 – 18 1:1:1 Randomi
Slide 11: Key Assessments
Key Assessments Adverse events Laboratory safety parameters (hematology, chemistry, urinalysis) Vital signs Cardiac examination (baseline, midway, and endpoint) Doppler echocardiograms 12-lead electrocardiogram SAFETY Analyses for ZX008 0.8 mg/kg/day vs. Placebo, and ZX008 0.2 mg/kg/day vs. Placebo:
Slide 12: Design of Stiripentol + ZX008 Phase 3 Study 1504
Design of Stiripentol + ZX008 Phase 3 Safety and Efficacy Study 1504 Same safety and efficacy assessments as Studies 1501 and 1502 Cohort 1 characterized the PK interaction of ZX008 with stiripentol in children leading to selection of ZX008 dose to be used in Cohort 2 Randomized, double-blind, place
Slide 13: PBPK Model Used to Determine Equivalent Doses of ZX008
PBPK Model Used to Determine Equivalent Doses of ZX008 With and Without Co-administration of Stiripentol Regimen ZX008 levels are increased in the presence of the “stiripentol regimen.” Study 1504 Cohort 2 dose of 0.5mg/kg/day produce exposure levels equivalent to 0.8 mg/kg/day dose in Studies 1501
Slide 14: ZX008 Dravet Syndrome Phase 3 Progress
Good acceleration of enrollment during Q4 2016; positive momentum anticipated to continue through Q1 2017 Data from identical trials (1501 and 1502) pooled into a single analysis dataset and reported as two trials, sequentially Enables earliest evaluation of benefit/risk Consistent with original dev
Slide 15: ZX008 Market Research: Physician Perspectives
ZX008 Market Research: Physician Perspectives Primary marketing research conducted by bioStrategies Group, May 2015. N=31 Neurologists (US and EU) Majority of physicians ‘Strongly Recommend’ ZX008 Clinician recommendations made in the context of having all currently approved AEDs available, as well
Slide 16: Lennox Gastaut Syndrome: Refractory, Debilitating Childhood-Onset Epilepsy
Lennox Gastaut Syndrome Onset peaks 5-7 years of age Characterized by clinical triad Multiple seizure types, including drop seizures Cognitive impairment Characteristic EEG abnormality Underlying etiologies ~66% - Brain abnormalities (malformation, infection, hypoxia) ~33% - unknown No known genetic
Slide 17: Add-On Therapy with ZX008 in Lennox Gastaut Syndrome
Add-On Therapy with ZX008 in Lennox Gastaut Syndrome Interim Results from a Phase 2 Dose-Finding Study Phase 2 Open Label, 20-Week, Dose Finding Trial of ZX008 as an Add-on Anticonvulsive Therapy 13 Patients Enrolled to Date (Average Age 11.4 Years) With a Minimum of 12 Weeks of Treatment Failed a m
Slide 18: Clinical and Regulatory Plan for ZX008 in Lennox Gastaut Syndrome
Clinical and Regulatory Plan for ZX008 Development in Lennox Gastaut Syndrome Propose to conduct one global clinical study in LGS leveraging study sites participating in the current Dravet syndrome studies Two ZX008 doses compared to placebo using a study design similar to the on-going safety and ef
Slide 19: Establishing Product Protection
Establishing Product Protection ORPHAN DRUG STATUS Provides 7 Years in U.S. and 10 Years of Market Exclusivity in E.U. Further 3 Years in E.U. Due to Clinical Development via a Pediatric Investigational Plan PATENT APPLICATIONS Several Patent Families Being Pursued Globally Including Method(s) of Us
Slide 20: Multiple Milestones in 2017 for Creating Value
Multiple Milestones in 2017 for Creating Value IND Approval to Initiate Phase 3 in LGS (Q1 2017) First Phase 3 Results in Dravet Syndrome (Q2 2017) Results From Remaining Phase 3 Trials in Dravet Syndrome (Q3/4 2017) Potential NDA / MAA Submissions for Dravet Syndrome (Q4 2017) Phase 3 Start in LGS
Slide 21: Financial Highlights
Financial Highlights Cash (as of 12-31-16) $91.6 M Debt (1) (as of 09-30-16) $20.0 M Common Shares Outstanding (as of 9-30-16) 24.8 M Fully Diluted Shares (2) (as of 9-30-16) 30.2 M Excludes $7.0 million working capital advance from Endo International Fully diluted shares include options to purchase
Slide 22: Highly Focused on Orphan CNS Disorders
HIGHLY FOCUSED ON ORPHAN CNS DISORDERS DRAVET SYNDROME PHASE 3 RESULTS ON TRACK FOR Q2 2017 EXPERIENCED TEAM IN PLACE FULLY FUNDED THROUGH 2017 Planning LGS Phase 3 Initiation in miD-2017 NASDAQ: ZGNX